Jefferies Believes Amphastar Pharmaceuticals (NASDAQ: AMPH) Won’t Stop Here

By Jason Carr

Jefferies analyst David Steinberg reiterated a Buy rating on Amphastar Pharmaceuticals (AMPHResearch Report) on November 9 and set a price target of $26. The company’s shares opened today at $21.19, close to its 52-week high of $21.65.

According to, Steinberg is a 4-star analyst with an average return of 9.0% and a 48.4% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals Plc, Pacira Pharmaceuticals, and Menlo Therapeutics Inc.

Currently, the analyst consensus on Amphastar Pharmaceuticals is a Strong Buy with an average price target of $24, implying a 13.3% upside from current levels. In a report issued on November 9, Wells Fargo also maintained a Buy rating on the stock.


See today’s analyst top recommended stocks >>

The company has a one-year high of $21.65 and a one-year low of $14.40. Currently, Amphastar Pharmaceuticals has an average volume of 168.5K.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Richard Prins, a Director at AMPH sold 10,000 shares for a total of $178,100.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.